Sector News

Sanofi to create massive standalone API producer by melding 6 sites in Europe; IPO to come

February 26, 2020
Life sciences

New CEO Paul Hudson has pledged to squeeze €2 billion out of Sanofi’s annual costs in a couple of years through a mix of methods that leans heavily on clamping down on its manufacturing budgets. It has now announced a plan that it says will not only do that but add to its top line.

The French drugmaker today trumpeted plans to create the world’s second-largest API production operation by clumping together its six API manufacturing sites in Europe and the U.K. It said the operation, with 3,100 employees, is projected to have about €1 billion in sales by 2022.

Sanofi intends to decide by then whether to float an IPO for the new French-based company on Euronext Paris. It said the company, in which it will hold a 30% share, will be debt-free to enhance its investment ability.

“With this endeavor, this new entity would be agile as a standalone company, and able to unlock its growth potential, especially in capturing new third-party sales and all the opportunities of a market growing at a pace of 6% per year,” Philippe Luscan, executive VP of Sanofi global Industrial affairs said in a statement.

Sanofi says it will include its API commercial and development operations with its API manufacturing sites Brindisi, Italy: Frankfurt, Germany; Haverhill, UK; St Aubin les Elbeuf and in Vertolaye, France and in Újpest, Hungary.

The company said that such a business would help alleviate drug shortages and balance Europe’s “heavy reliance on API sourced from the Asian region.”

That, of course, has been top of mind as COVID-19 has wreaked havoc on manufacturing in China, the world’s Walmart of API sales. It says that statistics show 60% of global API production comes from China and India.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach